Insight Molecular Diagnostics is a clinical-stage diagnostics company focused on organ-transplant monitoring. Its lead product, GraftAssureDx, is a test kit designed to measure dd-cfDNA in local hospital labs. Because the company has not yet received FDA authorization to sell the kit commercially, its reported revenue remains small and the story is driven less by quarterly sales than by regulatory progress and launch readiness. The third quarter of 2026 report therefore matters most as a checkpoint on the company's transition from a research-stage developer to a commercialized transplant-testing business, and as a signal of how efficiently management is controlling costs while awaiting a pivotal regulatory decision. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the third quarter of 2026, Insight Molecular Diagnostics reported revenue of approximately $559,000, compared with about $260,000 in the third quarter of 2025. Most revenue came from laboratory services performed at the company's CLIA-certified laboratory in Tennessee, along with $21,000 in research-use-only kitted product sales, versus zero in the prior-year period.
Gross profit reached $420,000, representing a 75.1% gross margin, up from $139,000 and a 53.5% margin a year earlier. Operating expenses declined to $4.1 million from $11.2 million in the year-ago quarter, reflecting the wind-down of heavy research and development spending tied to the company's FDA submission.
On the bottom line, the company reported a net loss of $0.10 per share, which beat the consensus estimate of a $0.24 loss. Revenue of roughly $560,000 also came in above the consensus estimate of about $215,000. Management reiterated that it expects no material kitted-product revenue until after regulatory authorization of GraftAssureDx, keeping the company "pre-revenue" in its core commercial strategy.
Heading into the report, sentiment around IMDX was shaped by the company's pre-revenue status and its pending FDA review of GraftAssureDx. The third-quarter results offered a mix of signals: sharply higher gross margins and lower operating expenses demonstrated improving cost discipline, while revenue, though more than doubled year over year, remained small in absolute terms. The earnings-per-share beat relative to consensus reflected narrower losses, but the shares have traded under meaningful pressure over the trailing year, a pattern consistent with a company that is still largely valued on future regulatory milestones rather than current financial performance. Investors are likely to weigh the improving expense trajectory against the still-uncertain timing of commercial authorization.
The central catalyst for Insight Molecular Diagnostics is the FDA's decision on GraftAssureDx, the kitted version of its kidney-transplant rejection monitoring assay. The company submitted its data package for marketing authorization in March 2026, and a positive decision would mark the company's transition to genuine commercial sales.
Beyond regulatory approval, investors should watch reimbursement progress, particularly through MolDX, a Medicare program that establishes coverage for molecular diagnostic tests. Securing favorable coverage would support both adoption and pricing once the kit reaches the market.
Commercial execution is another key factor. The company recently appointed a Senior Vice President of Sales and has been building out its go-to-market foundation. Management has also signaled plans to expand the GraftAssure platform beyond kidney transplant monitoring into heart transplant testing over time.
Finally, cash management remains important. With revenue still modest, the company's cash burn and any future financing activity will influence its ability to fund commercialization and further clinical development. Investors should monitor operating expense trends and cash reserves alongside regulatory and reimbursement milestones.
In my own research process, I frequently rely on Tickeron’s AI-powered tools to cross-check fundamentals and spot comparable names in the diagnostics space. The AI Screener stands out for its ability to filter thousands of stocks using technical patterns, fundamentals, and custom criteria, which helps surface relevant trade ideas and benchmark opportunities more efficiently than manual reviews. This approach has proven useful when evaluating pre-revenue companies like IMDX against sector peers.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMDX as a result. In 81 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IMDX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 46 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMDX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.826) is normal, around the industry mean (67.298). P/E Ratio (-1.638) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. IMDX's P/S Ratio (71.942) is very high in comparison to the industry average of (9.775).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
Industry MedicalSpecialties